The US FTC files amicus curiae brief supporting generics’ claim in patent dispute (Actelion Pharms/Apotex)

U.S. FTC files amicus curiae brief supporting generics’ claim in patent dispute* On 11 March 2013 the U.S. Federal Trade Commission (“FTC”) filed an amicus curiae brief in the case Actelion Pharms Ltd. V. Apotex Inc. which is being heard in the U.S. District Court for New Jersey supporting the defendants’ claim of the plaintiff’s anticompetitive use of Risk Evaluation and Mitigation Strategies (“REMS”) [1]. This case is about the generic access to branded products for making Hatch-Waxman patent challenges. Actelion sued Apotex, Actavis and Roxane (“Apotex”) for a declaratory judgment to affirm the legality

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Author

  • DLA Piper Weiss-Tessbach (Vienna)

Quotation

Nicole Daniel, The US FTC files amicus curiae brief supporting generics’ claim in patent dispute (Actelion Pharms/Apotex), 11 March 2013, e-Competitions Bulletin Amicus curiae, Art. N° 57332

Visites 163

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues